A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

Recruiting Observational Study
ATTR Amyloidosis With Cardiomyopathy ATTR-CM ATTR Amyloidosis Wild Type Mitral Regurgitation Tricuspid Regurgitation
No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
600 (estimated)
Sponsor
Medical University of Vienna · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurg…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of ATTR-CM according to current diagnostic criteria * Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR/TR) parameters, performed within ±6 months of diagnosis * Age ≥ 18 years * Willingness to p…
Contacts

Christian Nitsche, Priv.-Doz. Dr., PhD

+4314040048590

christian.nitsche@meduniwien.ac.at

CONTACT

Laurenz Hauptmann, Dr.

+4314040048590

Laurenz.hauptmann@meduniwien.ac.at

CONTACT